

CURRICULUM VITAE**INFORMAZIONI
PERSONALI**

Nome	Giampiero Girolomoni
Luogo e data di nascita	
Codice Fiscale	
Qualifica	Professore ordinario e Direttore Sezione Dermatologia e Venereologia, Dipartimento di Medicina, Scuola di Medicina e Chirurgia, Università di Verona; Direttore della U.O.C. Dermatologia dell'Azienda Ospedaliera Universitaria Integrata di Verona
Telefono ufficio	045/8122547 Fax 045/8027315
E-mail	giampiero.girolomoni@univr.it

**TITOLI DI STUDIO E
PROFESSIONALI –
ESPERIENZE LAVORATIVE**

Titoli di studio	1976 Diploma di maturità classica – Liceo Mamiani, Pesaro 1983 Laurea in Medicina e Chirurgia – Università di Modena Iscritto Ordine dei Medici PU1622
Altri titoli di studio	1986 Specialista in Dermatologia e Venereologia– Università di Modena
Esperienze professionali (incarichi ricoperti)	1988–1990 Immunodermatology Fellow, Visiting Instructor, Dipart. di Dermatologia, University of Texas Southwestern Medical School, Dallas, TX, USA 1990–1994 Assistente Medico, Clinica Dermatologica, Università di Modena 1994–2004 Direttore Laboratorio di Ricerca di Immunologia; Primario Seconda Divisione di Dermatologia, Direttore Dipartimento di Dermatologia Clinica, Istituto Dermopatico dell'Immacolata, Roma 2005–2018 Direttore scuola di specializzazione in Dermatologia e Venereologia, Università di Verona
Capacità linguistiche	Ottima conoscenza scritta e parlata della lingua inglese
Premi e Onorificenze	1990 Outstanding Research Award: The Upjohn Company and the Department of Dermatology, UTSMC, Dallas, TX 1993 Scientific award: 2 nd Tricontinental Meeting JSID/SID/ESDR. Kyoto 2015 Pro-meritis Award: 2015 European Dermatology Forum, Bern 2016 Ehrenmitglied, Deutsche Dermatologische Gesellschaft 2017 Commendatore, Ordine al Merito della Repubblica Italiana, Presidenza del Consiglio dei Ministri 2017 Scientific Achievement Award, European Academy of Dermatology and Venereology, Geneva 2018 Marchigiano dell'Anno 2017. Centro Studi Marche “Giuseppe Giunchi” – Senato della Repubblica 2018 Membro corrispondente Società Svizzera di Dermatologia e Venereologia 2019 Presidente emerito Società Italiana di Dermatologia (Sidemast) 2020 Certificate of appreciation International League of Dermatological Societies
Attività Scientifiche	Fisiopatologia delle reazioni immunitarie cellulo-mediate della cute, immunofarmacologia ed epidemiologia delle malattie infiammatorie croniche della cute. Dermatologia clinica: malattie cutanee nell'immunodepresso,

	reazioni cutanee da farmaci, manifestazioni cutanee delle malattie interne, complicanze cardio-metaboliche delle malattie infiammatorie croniche. Esperienze acquisite nel settore scientifico oggetto di sperimentazione secondo le norme di Buona Pratica Clinica (GCP), maturate nell'ambito di numerosi studi clinici nonché dell'assistenza ai pazienti. Principal investigator in oltre 150 trial clinici internazionali e nazionali. Past president European Dermatology Forum (EDF; 2011–2012) e Società Italiana di Dermatologia (Sidemast; 2014–2016). Editor della sezione Clinical Immunology di Vaccines (Basel). Associate Editor di Frontiers in Medicine (Dermatology). Membro del Comitato editorial di European Journal of Dermatology, the Journal of the German Society of Dermatology, the Journal of Dermatology, European Annals of Allergy and Clinical Immunology. Presidente e/o responsabile scientifico di 164 congressi nazionali o internazionali. Letture a invito 1988–2022: 986.
--	--

Pubblicazioni Scientifiche	Co-autore di 450 articoli originali, 213 reviews, 89 capitoli di libri o monografie, 1145 abstracts per congressi, e co-autore o co-editore di 5 libri. IF globale >3100; IF medio = 4.88; Citazioni >35000; H-index: 101, i10 H-index: 393 (Scholar). ORCID: 0000-0001-8548-0493; Scopus ID: 7005176426; Publons ID: AAC-3405-2022
-----------------------------------	--

PRINCIPALI PUBBLICAZIONI 2020–2022:

1. Gisondi P, Rovaris M, Piaserico S, Girolomoni G. Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis. *Br J Dermatol* 182:175–179, 2020.
2. Fania L, Morelli M, Scarponi C, Mercurio L, Scopelliti F, Cattani G, Scaglione GL, Tonanzi T, Pilla MA, Pagnanelli G, Mazzanti C, Girolomoni G, Cavani A, Madonna S, Albanesi C. Paradoxical psoriasis induced by TNF- α blockade shows immunological features typical of the early phase of psoriasis development. *J Pathol Clin Res* 6:55–68, 2020.
3. Patruno C, Amerio P, Chiricozzi A, Costanzo A, Cristuado A, Cusano F, Foti C, Girolomoni G, Guarneri F, Naldi L, Offidani A, Pigatto P, Prignano F, Stingeni L, Calzavara Pinton P. Optimizing a clinical guidance for diagnosis of atopic dermatitis in adults: joint recommendations of the Italian Society of Dermatology and Venereology (SIdMaST), Italian Association of Hospital Dermatologists (ADOI), and Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA). *G Ital Dermatol Venereol* 155:1–7, 2020.
4. Calzavara-Pinton P, Fabbrocini G, Girolomoni G, Mattiucci A, Micali G, Musumeci ML, Patruno C, Pellacani G, Rossi MT, Stingeni L, Castello M. Topical tacrolimus in adult atopic dermatitis: a consensus based on a 15-year experience. *G Ital Dermatol Venereol* 155:8–13, 2020.
5. Sciattella P, Pellacani G, Pigatto PD, Patrizi A, Peris K, Calzavara Pinton P, Girolomoni G, Lanati EP, D'Ausilio A, Mennini FS. The burden of atopic dermatitis in adults in Italy. *G Ital Dermatol Venereol* 155:19–23, 2020.
6. Maurelli M, Gisondi P, Girolomoni G. Visual vignette. Metastatic glucagonoma. *Endocr Pract* 26:253, 2020.
7. Gisondi P, Bellinato F, Girolomoni G, Albanesi C. Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities. *Front Pharmacol* 11:117, 2020.
8. Tonin B, Pizzolato M, Furci A, Girolomoni G. Cutaneous pili migrans. *Open J Clin Med Case Rep* 1635, 2020.
9. Vimercati L, De Maria L, Caputi A, Sabrina E, Cannone S, Mansi F, Cavone D, Romita P, Argenziano G, Di Stefani A, Parodi A, Peris K, Scalvenzi M, Girolomoni G, Foti C. Non-melanoma skin cancer in outdoor workers: a study on actinic keratosis in Italian navy personnel. *Int J Environ Res Public Health* 17:E2321, 2020.
10. Maurelli M, Bellinato F, Gisondi P, Girolomoni G. Persistent localized hypertrichosis in a Caucasian child at sites of DTPa and chickenpox vaccination. *Vaccine* 38:3808–3809, 2020.
11. Virgili A, Borghi A, Cazzaniga S, Di Landro A, Naldi L, Minghetti S, Fierro MT, Verrone A, Caproni M, Micali G, Gaspari V, Papini M, Di Lernia V, Germi L, Girolomoni G, Belloni Fortina A, Cannavò SP, Bilenchi R, Corazza M. Gender differences in genital lichen sclerosus: data from a multicenter Italian study on 729 consecutive cases. *G Ital Dermatol Venereol* 155:155–160, 2020.
12. de Bruin-Weller M, Gadkari A, Auziere S, Simpson EL, Puig L, Barbarot S, Girolomoni G, Papp K, Pink AE, Saba G, Werfel T, Eckert L. The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada. *J Eur Acad Dermatol Venereol* 34:1026–1036, 2020.
13. Maurelli M, Gisondi P, Danese E, Gelati M, Papagrigoraki A, del Giglio M, Lippi G, Girolomoni G. Psoriasin (S100A7) is increased in serum of patients with moderate to severe psoriasis. *Br J Dermatol* 182:1479–1506, 2020.
14. Alexander H, Paller AS, Traidl-Hoffmann C, Beck LA, De Benedetto A, Dhar S, Girolomoni G, Irvine A, Spuls P, Su J, Thyssen J, Vestergaard C, Weinstein M, Werfel T, Wollenberg A, Deleuran M, Flohr C. The role of bacterial skin

- infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group. *Br J Dermatol* 182:1331–1342, 2020.
15. Bellinato F, Maurelli M, Colato C, Girolomoni G. Amicrobial pustulosis of the folds: report of three new cases. *Indian J Dermatol* 65:323–324, 2020.
 16. Chiricozzi A, Maurelli M, Gori N, Argenziano G, De Simone C, Calabrese G, Girolomoni G, Peris K. Dupilumab improves clinical manifestations, symptoms and quality of life in adult patients with chronic nodular prurigo. *J Am Acad Dermatol* 83:39–45, 2020.
 17. Egeberg A, Girolomoni G, Feldman SR, Radtke MA, Carrascosa JM, Ghil J, Keum JW, Lee J, Seo H. Real world SB4 (Etanercept Biosimilar) use in patients with psoriasis: data from the British Association of Dermatologists Biologic Interventions Register (BADBIR). *J Drugs Dermatol* 19:316–318, 2020.
 18. Hadaschik E, Eming R, French LE, Girolomoni G, Hertl M, Jolles S, Karpati S, Steinbrink K, Stingl G, Volc-Platzter B, Zillikens D, Enk A. Europäische Leitlinien (S1) für die Verwendung von hochdosierten intravenösen Immunglobulinen in der Dermatologie. *Hautarzt* 71:542–552, 2020.
 19. Tonin B, Geat D, Girolomoni G. Bleomycin-induced flagellate dermatitis: a case report. *Serbian Journal of Dermatology and Venereology* 12:21–24, 2020.
 20. Bellinato F, Gisondi P, Girolomoni G. A dermatologist perspective in the pharmacological treatment of patients with psoriasis and psoriatic arthritis. *Expert Rev Clin Pharmacol* 13:481–491, 2020.
 21. Dal Bello G, Gisondi P, Idolazzi L, Girolomoni G. Psoriatic arthritis and diabetes mellitus: a narrative review. *Rheumatol Ther* 7:271–285, 2020.
 22. Gisondi P, Zaza, Del Giglio M, Rossi M, Iacono V, Girolomoni G. Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment. *J Am Acad Dermatol* 83:285–287, 2020.
 23. Gisondi P, Geat D, Conti A, Dapavo P, Piaserico S, De Simone C, Bianchi L, Costanzo A, Malagoli P, Malara G, Micali G, Naldi L, Offidani M, Patrizi A, Prignano F, Parodi A, Rongioletti F, Calzarava-Pinton P, Girolomoni G. TNF- α inhibitors biosimilars as first line systemic treatment for moderate to severe chronic plaque psoriasis. *Expert Rev Clin Immunol* 16:591–598, 2020.
 24. Gisondi P, Virga C, Piaserico S, Meneguzzo A, Odorici G, Conti A, Girolomoni G. Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis. *Br J Dermatol* 183:397–398, 2020.
 25. Bellinato F, Maurelli M, Gisondi P, Girolomoni G. Clinical features and treatments of transient acantholytic dermatosis (Grover's disease): A systematic review. *J Dtsch Dermatol Ges* 18:826–833, 2020.
 26. Tonin B, Geat D, Girolomoni G. A case of kerion celsi caused by *Trichophyton tonsurans*. *Pediatr Int* 62:1007–1008, 2020.
 27. Gisondi P, Bellinato F, Conti A, Dapavo P, Piaserico S, De Simone C, Chiricozzi A, Dattola A, Malagoli P, Malara G, Campanati A, Burlando M, Esposito M, Girolomoni G. Consensus on the place in therapy of TNF- α inhibitors in the treatment of patients with chronic plaque psoriasis. *J Eur Acad Dermatol Venereol* 34:e470–e472, 2020.
 28. Tonin B, Colato C, Bruni M, Girolomoni G. Late granuloma formation secondary to hyaluronic acid injection. *Dermatol Online J* 2020;26:13030/qt9fj4f3ts.
 29. Pahar B, Madonna S, Das, Albanesi C, Girolomoni G. Immunomodulatory role of the antimicrobial LL-37 peptide in autoimmune diseases and viral infections. *Vaccines (Basel)* 8:E517, 2020.
 30. Chiricozzi A, Maurelli M, Peris K, Girolomoni G. Targeting IL-4 for the treatment of atopic dermatitis. *Immunotargets Ther* 9:151–156, 2020.
 31. Gisondi P, Girolomoni G. Undertreatment in adult patients with moderate-to-severe atopic dermatitis and other inflammatory skin diseases. *J Eur Acad Dermatol Venereol* 34:2168–2169, 2020.
 32. Girolomoni G. Job: the prototypic dermatological patient Comments on a painting by Marcello Fogolino. *J Eur Acad Dermatol Venereol* 34:2175–2176, 2020.
 33. Tonin B, Catenaro R, Girolomoni G, Ghimenton C, Gisondi P. Pseudoepitheliomatous, keratotic and micaceous balanitis mimicking lichen sclerosus et atrophicus. *Dermatol Online* 2020;26:13030/qt7c33g14w
 34. Cork M, Eckert L, Simpson EL, Armstrong A, Barbarot S, Puig L, Girolomoni G, de Bruin-Weller M, Wollenberg A, Kataoko Y, Remitz A, Beissert S, Mastey V, Ardeleanu M, Chen Z, Gadkari A, Chao J. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. *J Dermatolog Treat* 31:606–614, 2020.
 35. Gisondi P, Girolomoni G. Brodalumab in the treatment of chronic plaque psoriasis. *Expert Opin Biol Ther* 20:1175–1185, 2020.
 36. Gisondi P, Bellinato F, Girolomoni G. Topographic differential diagnosis of chronic plaque psoriasis: challenges and tricks. *J Clin Med* 9:3594, 2020.

37. Tonin B, Geat D, Girolomoni G. An intriguing genital eruption in a traveler returning from Philippines. *Open J Clin Med Case Rep* 1649, 2020.
38. Tonin B, Pizzolato P, Furci A, Girolomoni G. Cutaneus pili mirans. *Open J Clin Med Case Rep* 1535, 2020.
39. Tonin B, Catenaro R, Gisondi P, Girolomoni G. Mycobacterium marinum infection acquired from a domestic aquarium. *Open J Clin Med Case Rep* 1659, 2020.
40. Gisondi P, Bellinato F, Chiricozzi A, Girolomoni G. The risk of COVID-19 infection in patients with moderate to severe plaque psoriasis receiving systemic treatments. *Vaccines (Basel)* 8:E728, 2020.
41. Chiricozzi A, Gisondi P, Bellinato F, Girolomoni G. Immune response to vaccination in psoriatic patients treated with systemic therapies. *Vaccines (Basel)* 8:E769, 2020.
42. Gisondi P, Piaserico S, Bordin C, Alaibac M, Girolomoni G, Naldi L. Cutaneous manifestations of SARS-CoV-2 infection: a clinical update. *J Eur Acad Dermatol Venereol* 34:2499–2504, 2020.
43. Barker J, Girolomoni G, Egeberg A, Gonçalves J, Pieper B, Kang T. Anti-TNF biosimilars in psoriasis: From scientific evidence to real-world experience. *J Dermatolog Treat* 31:794–800, 2020.
44. Dattola A, Balato A, Megna M, Gisondi P, Girolomoni G, De Simoni C, Caldarola G, Cama E, Piaserico S, Fargnoli MC, Fidanza R, Parodi A, Burlando M, Offidani A, Diotallevi F, Potenza C, Conti A, Chiricozzi A, Campione E, Bianchi L. Certolizumab for the treatment of psoriasis and psoriatic arthritis: A multicentre Italian study. *J Eur Acad Dermatol Venereol* 34:2939–2845, 2020.
45. Tessari G, Maggiore U, Zaza G, Nguefouet Momo RE, Nacchia F, Boschiero L, Sandrini S, Naldi L, Gotti E, Campise M, Messa P, Palmisano A, Capelli I, Minetti E, Rossini M, Girolomoni G. Mortality from cancer is not increased in kidney transplant recipients compared to the general population: a competing risk analysis. *J Nephrol* 33:1309–1319, 2020.
46. Maurelli M, Colato C, Tessari G, Girolomoni G. Lichen planus pilaris effectively treated with brodalumab. *Dermatol Ther*, 33:e13967, 2020.
47. Dal Bello G, Maurelli M, Schena D, Girolomoni G, Gisondi P. Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients. *Dermatol Ther* 33:e13979, 2020.
48. Gisondi P, Bellinato F, Bruni M, De Angelis G, Girolomoni G. Methotrexate versus secukinumab safety in psoriasis patients with metabolic syndrome. *Dermatol Ther* 33:e14281, 2020.
49. Dal Bello G, Colato C, Rosina P, Girolomoni G. Nivolumab induced morphea. *G It Dermatol Venereol* 155:701–702, 2020.
50. Mercurio L, Lulli D, Mascia F, Dellambra E, Scarponi C, Morelli M, Valente C, Carbone M, Pallotta S, Girolomoni G, Albanesi C, Pastore S, Madonna S. Intracellular Insulin-like Growth Factor Binding Protein 2 (IGFBP2) contributes to senescence of keratinocytes in psoriasis by stabilizing the cytoplasmic levels of p21. *Aging (Albany NY)* 12:6823–6851, 2020.
51. Gisondi P, Geat D, Lippi G, Montagnana M, Girolomoni G. Increased red blood cell distribution width in patients with plaque psoriasis. *J Med Biochem* 40:199–201, 2021.
52. Gisondi P, Geat D, Girolomoni G. Place of apremilast in the real-life treatment of patients with plaque psoriasis. *J Eur Acad Dermatol Venereol* 35:13, 2021.
53. Girolomoni G, Luger T, Nosbaum A, Gruben D, Romero W, Llamado LJ, DiBonaventura M. The economic and psychosocial comorbidity burden among adults with moderate-to severe atopic dermatitis in Europe. *Dermatol Ther (Heidelb)* 11:117–130, 2021.
54. Gisondi P, Talamonti M, Chiricozzi A, Piaserico S, Amerio P, Balato A, Bardazzi F, Calzavara Pinton P, Campanati A, Cattaneo A, Dapavo P, De Simone C, Dini V, Fargnoli M C, Flori M L, Galluzzo M, Guarneri C, Lasagni C, Lo Schiavo A, Loconsole F, Malagoli P, Malara G, Mercuri S R, Musumeci M L, Naldi L, Papini M, Parodi A, Potenza C, Prignano F, Rongioletti F, Stingeni L, Tiberio R, Venturini M, Bianchi L, Costanzo A, Cusano F, Girolomoni G, Offidani AM, Peris K. Treat-to-target approach for the management of patients with moderate-to-severe plaque psoriasis: consensus recommendations. *Dermatol Ther (Heidelb)* 11:235–252, 2021.
55. Patruno C, Napolitano M, Argenziano G, Peris K, Ortoncelli M, Girolomoni G, Offidani A, Ferrucci SM, Amoroso GF, Rossi M, Stingeni L, Malara G, Grieco T, Foti C, Gattoni M, Loi C, Iannone M, Talamonti M, Stinco G, Rongioletti F, Pigatto PD, Cristaudo A, Nettis E, Corazza M, Guarneri F, Amerio P, Esposito M, Belloni Fortina A, Potenza C, Fabbrocini G. Dupilumab therapy of atopic dermatitis of the elderly: a multi-centre, real-life study. *J Eur Acad Dermatol Venereol* 35:958–964, 2021.
56. Garcovich S, Maurelli M, Gisondi P, Peris K, Yosipovitch G, Girolomoni G. Itch as a distinctive feature of type 2 immunity mediated diseases. *Vaccines (Basel)* 9:333, 2021.
57. Esposito M, Giunta A, Gisondi P, Tambone S, Rovaris M, Manfreda V, Pirro F, Pellegrini C, Fargnoli MC, Bianchi L, Peris K, Girolomoni G. Satisfaction and attitudes toward systemic treatments for psoriasis: a cross-sectional study. *Dermatol Ther* 34:e14949, 2021.
58. Girolomoni G, de Bruin-Weller M, Aoki V, Kabashima K, Deleuran M, Puig L, Bansal A, Rossi AB. Nomenclature and clinical phenotypes of atopic dermatitis. *Ther Adv Chronic Dis* 12:1–20, 2021.

59. Bellinato F, Gisondi P, Maurelli M, Girolomoni G. IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: a case series with systematic literature review. *Dermatol Ther* 34:e14889, 2021.
60. Morelli M, Galluzzo M, Madonna S, Scarponi C, Scaglione GL, Galluccio T, Andreani M, Pallotta S, Girolomoni G, Bianchi L, Talamonti M, Albanesi C. HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58 and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis. *Expert Opin Biol Ther* 21:259–270, 2021.
61. Dal Bello G, Schena D, Colato C, Girolomoni G. Nodules of the thigh after brown recluse spider venom bite. A quiz. *Acta Derm Venereol* 101:adv400, 2021.
62. de Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G, Hercogová J, Hong CH, Katoh N, Pink AE, Richard MA, Shumack S, Silvestre JF, Weidinger S. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. *Acta Derm Venereol* 101:adv402, 2021.
63. Geat D, Giovannini M, Barlocco EG, Pertile R, Farina S, Pace M, Fillipeschi C, Girolomoni G, Cristofolini M, Baldo E. Characteristics associated with clinical response to Comano thermal spring water balneotherapy in pediatric patients with atopic dermatitis. *Ital J Pediatr* 47:91, 2021.
64. Geat D, Giovannini M, Barlocco EG, Pertile R, Pace M, Mori F, Novembre E, Girolomoni G, Cristofolini M, Baldo E. Assessing patients' characteristics and treatment patterns among children with atopic dermatitis. *Ital J Pediatr* 47:92, 2021.
65. Furci A, Del Giglio M, Bellinato F, Colato C, Girolomoni G. Coexistence of scleromyxedema and Sneddon syndrome. *JAAD Case Rep* 11:47–50, 2021.
66. Piaserico S, Gisondi P, Cazzaniga S, Girolomoni G, Calzavara-Pinton PG, Naldi L. Is SARS-CoV-2 screening test indicated for psoriasis patients candidate to biologic therapy? *J Eur Acad Dermatol Venereol* 35:e355–e357, 2021.
67. Maurelli M, Gisondi P, Colato C, Girolomoni G. Annually recurring erythema annulare centrifugum: a new case series with review of the literature. *Case Rep Dermatol* 13:282–288, 2021.
68. Patrino C, Fabbrocini G, Longo G, Argenziano G, Ferrucci SM, Stingeni L, Peris K, Ortoncelli M, Offidani A, Amoroso GF, Talamonti M, Girolomoni G, Grieco T, Iannone M, Nettis E, Foti C, Rongioletti F, Corazza M, Veneri MD, Napolitano M; Dupilumab for Atopic Dermatitis of the Elderly (DADE) Study Group. Effectiveness and safety of long-term dupilumab treatment in elderly patients with atopic dermatitis: a multicentre, real-life, observational study. *Am J Clin Dermatol* 22:581–586, 2021.
69. Chiricozzi A, Talamonti M, De Simone C, Galluzzo M, Gori N, Fabbrocini G, Marzano AV, Girolomoni G, Offidani AM, Rossi MT, Bianchi L, Cristaudo A, Fierro F, Stingeni L, Pellacani G, Argenziano G, Patrizi A, Pigatto P, Romanelli M, Savoia P, Rubegni P, Foti C, Milanese N, Belloni Fortin A, Bongiorno M, Grieco T, Di Nuzzo S, Fargnoli MC, Carugno A, Motolese M, Rongioletti F, Amerio P, Balestri R, Potenza C, Micali G, Patrino C, Zalaudek I, Lombardo M, Feliciani C, Cannavò S, Peris K. Management of the patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: data from the DA-COVID-19 registry. *Allergy* 76:1813–1824, 2021.
70. Bellinato F, Maurelli M, Colato C, Gisondi P, Girolomoni G. Alopecic and aseptic nodules of the scalp: A new case with a systematic review of the literature. *Clin Case Rep* 9:e04153, 2021.
71. Stingeni L, Hansel K, Antonelli E, Dal Bello G, Patrino C, Napolitano M, Fabbrocini G, Grieco T, Pellacani P, Fargnoli MC, Esposito M, Piras V, Zucca M, Girolomoni G. Atopic dermatitis in adolescents: effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy. *Dermatol Ther* 2021:e15035.
72. Bellinato F, Gisondi P, Girolomoni G. Latest advances for the treatment of chronic plaque psoriasis with biologics and oral small molecules. *Biologics* 15:247–253, 2021.
73. Pezzolo E, Mutlu U, Vernooij MK, Dowlatshahi EA, Gisondi P, Girolomoni G, Nijsten T, Ikram A, Wakkee M. The association of psoriasis with cognition, brain imaging markers and risk of dementia: the Rotterdam study. *J Am Acad Dermatol* 85:671–680, 2021.
74. Ingrassi G, Lipman ZM, Hawash AA, Girolomoni G, Yosipovitch G. The pruritogenic role of the type 2 immune response in diseases associated with chronic itch. *Exp Dermatol* 30:1208–1217, 2021.
75. Gisondi P, Piaserico S, Bordin C, Tozzi F, Alaibac M, Girolomoni G, Naldi L. Hydroxychloroquine safety: major cutaneous and extracutaneous adverse events. *Clin Exp Rheumatol* 39:1099–1107, 2021.
76. Gisondi P, Cazzaniga S, Di Leo S, Piaserico S, Bellinato F, Pizzolato M, Gatti A, Eccher A, Brunelli M, Saraggi D, Girolomoni G, Naldi L. Impact of the COVID-19 pandemic on melanoma diagnosis. *J Eur Acad Dermatol Venereol* 35:e714–e715, 2021.
77. Gisondi P, Geat D, Bellinato F, Spiazzi L, Danese E, Montagnana M, Lippi G, Girolomoni G. Psychological stress and salivary cortisol levels in patients with chronic plaque psoriasis. *J Pers Med* 11:1069, 2021.
78. Maurelli M, Bellinato F, Girolomoni G. Adrenergic urticaria successfully treated with omalizumab. *J Dermatol* 48:e541–e542, 2021.
79. Gisondi P, Geat D, Mattiucci A, Lombardo F, Santo A, Girolomoni G. Incidence of adverse cutaneous reactions to epidermal growth factor receptor inhibitors in patients with non-small cell lung cancer. *Dermatology* 237:929–933,

2021.

80. Moar A, Azzolini A, Tessari G, Schena D, Girolomoni G. Non-bullous pemphigoid: a single center retrospective study on disease characteristics. *Dermatology* 237:1039–1045, 2021.
81. Moar A, Azzolini A, Tessari G, Schena D, Girolomoni G. Reply to: Non-bullous pemphigoid: a yet-to-be defined disease entity. *Dermatology* 237:1048–1049, 2021.
82. Fargnoli MC, Esposito M, Ferrucci S, Girolomoni G, Offidani A, Patrizi A, Peris K, Costanzo A, Malara G, Pellacani G, Romanelli M, Amerio P, Cristaudo A, Flori ML, Motolese A, Betto P, Patruno C, Pigatto P, Sirna R, Stinco G, Zalaudek I, Bianchi L, Boccaletti V, Cannavò SP, Cusano F, Lembo S, Mozzillo R, Gallo R, Potenza C, Rongioletti F, Tiberio R, Grieco T, Micali G, Persechino S, Pettinato M, Pucci S, Savi E, Stingeni L, Romano A, Argenziano G. Real-life experience on efficacy and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. *J Dermatolog Treat* 32:507–513, 2021.
83. Bellinato F, Maurelli M, Schena D, Gisondi P, Girolomoni G. Clinical and immunological profile of patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. *Ital J Dermatol Venereol* 156:455–459, 2021.
84. Barker J, Green W, Baker H, Nadeem A, Gu D, Girolomoni G. Health economic assessment of optimal biological treatment for moderate-to-severe psoriasis. *Clin Drug Investig* 41:1011–1020, 2021.
85. Moar A, Maurelli M, Colato C, Schena D, Girolomoni G. Milia-like calcinosis cutis in Down's syndrome: A new case with a review of the literature. *Dermatol Online J* 25:9, 2021.
86. Dal Bello G, Colato C, Girolomoni G. Exfoliative cheilitis as a manifestation of factitial cheilitis in a young man. *Ital J Dermatol Venereol* 156:513–514, 2021.
87. Bellinato F, Maurelli M, Gisondi P, Girolomoni G. Cutaneous adverse reactions associated with SARS-CoV-2 vaccines. *J Clin Med* 10:5344, 2021.
88. Colato C, Maurelli M, Girolomoni G. Annular erythema: new and revisited variants. *New and Emerging Entities in Dermatology and Dermatopathology*. Rongioletti F, Smoller BR, Eds. Springer Nature Switzerland. Pag. 83–92, 2021.
89. Moar A, Bruni M, Schena D, Rigotti E, Colato C, Novelli A, Cesario C, Girolomoni G. Netherton syndrome plus atopic dermatitis: two new genetic mutations in the same patient. *Clin Case Rep* 9:e05108, 2021.
90. Geat D, Tonin B, Colato C, Girolomoni G. A case of porokeratosis with predominant follicular involvement. *Ital J Dermatol Venereol* 156:619–620, 2021.
91. Cassano N, Genovese G, Asero R, Crimi N, Cristaudo A, Dapavo P, De Pità O, Ferrucci F, Fierro MT, Foti C, Girolomoni G, Nettis E, Offidani A, Patrizi A, Pepe P, Pigatto P, Stingeni L, Marzano AV, Vena GA. Chronic spontaneous urticaria in clinical practice: A pilot survey about attitudes and perceptions on assessment, diagnostic work-up and dietary management. *Ital J Dermatol Venereol* 156:659–664, 2021.
92. Bellinato F, Maurelli M, Gisondi P, Girolomoni G. Clinical profile and co-infections of urethritis in males. *Ital J Dermatol Venereol* 156:681–685, 2021.
93. Maurelli M, Colato C, Giannetti L, Girolomoni G. Lymphoplasmocytic plaque of children: successful treatment with imiquimod. *Ital J Dermatol Venereol* 156 (Suppl 1):17–18, 2021.
94. Virga C, Maurelli M, Colato C, Girolomoni G. Idiopathic lichenoid and granulomatous dermatitis. *Ital J Dermatol Venereol* 156 (Suppl 1):92–93, 2021.
95. Bellinato F, Gisondi P, Girolomoni G. Risk of lympho-haematological malignancies in patients with chronic plaque psoriasis: a systematic review with meta-analysis. *J Am Acad Dermatol* 86:86–96, 2022.
96. Bellinato F, Maurelli M, Gisondi P, Girolomoni G. Acquired perforating dermatoses show increased levels of cutaneous advanced glycation end products. *Clin Exp Dermatol* 47:80–85, 2022.
97. Girolomoni G, Busà VM. Flare management in atopic dermatitis: from definition to treatment. *Ther Adv Chronic Dis* 13:1–9, 2022.
98. Gisondi P, Bellinato F, Girolomoni G. Skin adverse reactions to Sars-CoV-2 vaccination: a relevant responsibility issue for dermatologists. *J Eur Acad Dermatol Venereol* 36:165–166, 2022.
99. Senna G, Micheletto C, Piacentini G, Schiappoli M, Girolomoni G, Sala G, Allievi EG, Stassaldi A. Multidisciplinary management in type 2 inflammatory disease. *Multidiscip Respir Med* 17:813, 2022.
100. Gisondi P, Bellinato F, Targher G, Idolazzi L, Girolomoni G. Biologic disease modifying anti rheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. *Ann Rheum Dis* 81:68–73, 2022.
101. Hansel K, Patruno C, Antonelli E, Dal Bello G, Napolitano M, Fabbrocini G, Grieco T, Pellacani P, Fargnoli MC, Esposito M, Piras V, Zucca M, Girolomoni G, Stingeni L. Dupilumab in adolescents with moderate-to-severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic. *Clin Exp Dermatol* 47:165–167, 2022.
102. Costanzo A, Amerio P, Asero R, Chiricozzi A, Corazza M, Cristaudo A, Cusano F, Ferrucci SM, Nettis E, Patrizi A, Patruno C, Peris K, Picozza M, Stingeni L, Girolomoni G. Long-term management of moderate-to-severe adult atopic dermatitis: A Consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Association of Italian Territorial and Hospital Allergists and Immunologists (AAIITO), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA), and the Italian


- Society of Allergy, Asthma and Clinical Immunology (SIAAIC). *Ital J Dermatol Venereol* 157:1–12, 2022.
103. Cassano N, Genovese G, Asero R, Crimi N, Cristaudo A, Dapavo P, De Pità O, Ferrucci F, Fierro MT, Foti C, Girolomoni G, Nettis E, Offidani A, Patrizi A, Pepe P, Pigatto P, Stingeni L, Marzano AV, Vena GA. Therapeutic management of chronic spontaneous urticaria in clinical practice: Results from a pilot survey. *Ital J Dermatol Venereol* 157:33–38, 2022.
 104. Gisbert JP, Gaffney K, Young D, Ebberts H, Girolomoni G. Current evidence on the use of the adalimumab biosimilar SB5 (ImraldiTM): a multidisciplinary perspective. *Exp Opin Biol Ther* 22:109–121, 2022.
 105. Gisondi P, Fargnoli MC, Amerio P, Argenziano G, Bardazzi F, Bianchi L, Chiricozzi A, Conti A, Corazza M, Costanzo A, Dapavo P, De Simone C, Fabbrocini G, Feliciani C, Foti C, Girolomoni G, Guarneri C, Marzano AV, Micali G, Offidani AM, Parodi A, Pellacani G, Piaserico S, Prignano F, Romanelli M, Rongioletti F, Rubegni P, Stinco G, Stingeni L, Tomasini CF, Venturini M, Peris K7, Calzavara-Pinton PG. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. *Ital J Dermatol Venereol* 157 (Suppl 1):1–78, 2022.
 106. Gisondi P, Geat D, Ferrazzi A, Bellinato F, Girolomoni G. Hypochondriasis and personality traits of patients with chronic plaque psoriasis. *Dermatology* 238:276–282, 2022.
 107. Fargnoli MC, Esposito M, Ferrucci S, Girolomoni G, Offidani A, Patrizi A, Peris K, Costanzo A, Malara G, Pellacani G, Romanelli M, Amerio P, Cristaudo A, Flori ML, Motolese A, Betto P, Patruno C, Pigatto P, Peccianti C, Stinco G, Zalaudek I, Bianchi L, Boccaletti V, Cannavo SP, Cusano F, Lembo S, Mozzillo R, Gallo R, Potenza C, Rongioletti F, Tiberio R, Grieco T, Micali G, Persechino S, Pettinato M, Pucci S, Stingeni L, Caruso C, Argenziano G. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. *J Dermatolog Treat* 33:1146–1149, 2022.
 108. Gisondi P, Geat D, Maurelli M, Degli Esposti L, Bellinato F, Girolomoni G. Cost per responder analysis of secukinumab versus adalimumab in the treatment of psoriatic disease. *Vaccines* 10:646, 2022.
 109. Bellinato F, Adami G, Valenti S, Benini C, Gatti D, Idolazzi L, Fassio A, Rossini M, Girolomoni G, Gisondi P. Association between short-term exposure to environmental air pollution and psoriasis flare. *JAMA Dermatol* 158:375–381, 2022.
 110. Bellinato F, Rosina P, Sina S, Girolomoni G. Primary nodular localized cutaneous amyloidosis of the scalp associated with systemic lupus erythematosus. *Arch Rheumatol* 37:145–147, 2022.
 111. Chiricozzi A, Maurelli M, Gori N, Gisondi P, Caldarola G, De Simone C, Peris K, Girolomoni G. Biologic agents targeting IL-13 for atopic dermatitis. *Expert Opin Biol Ther* 22:651–659, 2022.
 112. Prignano F, Brunasso AMG, Fabbrocini G, Argenziano G, Bardazzi F, Borroni R, Burlando M, Cagni AE, Campione E, Cinotti E, Cuccia A, Dastoli S, De Pasquale R, De Simone C, Di Lernia V, Dini V, Fargnoli MC, Faure E, Giacchetti A, Giofrè C, Girolomoni G, Lasagni C, Lembo S, Loconsole F, Montesu MA, Pella P, Pigatto P, Richetta AG, Stroppiana E, Venturini M, Zichichi L, Piaserico S. Sharing patient and clinician experiences of moderate-to-severe psoriasis: a nationwide Italian survey and expert opinion to explore barriers impacting upon patient wellbeing. *J Clin Med* 11:2081, 2022.
 113. Chiricozzi A, Di Nardo L, Talamonti M, Galluzzo M, De Simone C, Fabbrocini G, Marzano AV, Girolomoni G, Offidani AM, Calzavara-Pinton P, Bianchi L, Cristaudo A, Fierro F, Stingeni L, Pellacani G, Argenziano G, Patrizi A, Pigatto P, Romanelli M, Savoia P, Rubegni P, Foti C, Milanesi N, Belloni Fortin A, Bongiorno M, Grieco T, Di Nuzzo S, Fargnoli MC, Carugno A, Motolese M, Rongioletti F, Amerio P, Balestri R, Potenza C, Micali G, Patruno C, Zalaudek I, Lombardo M, Feliciani C, Antonelli F, Ferrucci SM, Guarneri F, Peris K. Patients withdrawing dupilumab monotherapy for COVID-19-related reasons showed similar disease course compared to patients continuing dupilumab therapy. *Dermatitis* 33:e25–e29, 2022.
 114. Bruni M, Moar A, Schena D, Girolomoni G. A case of nivolumab-induced bullous pemphigoid successfully treated with dupilumab. *Dermatol Online J* 28:6, 2022.
 115. Bellinato F, Goio I, Malara G, Rosato A, Targher G, Girolomoni G, Gisondi P. Non-alcoholic fatty liver disease is associated with reduced glomerular filtration rate in patients with chronic plaque psoriasis. *J Cutan Med Surg* 26:249–255, 2022.
 116. Malagoli P, Dapavo P, Pavia G, Amoroso F, Argenziano G, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dini V, Girolomoni G, Guarneri C, Loconsole F, Narcisi A, Sampogna F, Travaglini M, Costanzo A. Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: an Italian 192 weeks multicentric retrospective study – IL PSO (Italian landscape psoriasis). *Dermatol Ther* 2022;e15608.
 117. Moar A, Maurelli M, Geat D, Girolomoni G. A case of genital primary syphilis with superimposed impetigo. *Ital J Dermatol Venereol* 157:291–292, 2022.
 118. Bellinato F, Gisondi P, Mantovani A, Girolomoni G, Targher G. Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: a systematic review and meta-analysis of observational studies. *J Endocrinol Invest* 45:1277–1288, 2022.
 119. Bellinato F, Gisondi P, Mason E, Ricci P, Maurelli M, Girolomoni G. Real-life effectiveness of adalimumab biosimilars in patients with chronic plaque psoriasis. *Dermatol Ther (Heidelb)* 12:1303–1311, 2022.

120. Maurelli M, Bellinato F, Gisondi P, Girolomoni G. Reduction of cutaneous advanced glycation end products levels after effective psoriasis treatment. *J Eur Acad Dermatol Venereol* 36:e629–e631, 2022.
121. Bellinato F, Gisondi P, Girolomoni G. Monkeypox virus infection: what dermatologist needs to know. *J Eur Acad Dermatol Venereol* 36:e656–e658, 2022.
122. Gisondi P, Bellinato F, Girolomoni G. Clinical characteristics of patients with pustular psoriasis: a single-center retrospective observational study. *Vaccines (Basel)* 10:1171, 2022.
123. Patrizi A, Costanzo A, Patruno C, Busà VM, Chiricozzi A, Girolomoni G. Unmet needs in atopic dermatitis management: an expert consensus. *J Dermatolog Treat* 00:000–000, 2022.
124. Bellinato F, Rosina P, Tonin B, Gisondi P, Girolomoni G. Predictors of subsequent primary melanoma: a case-control study. *Arch Dermatol Res* 00:000–000, 2022.
125. Dal Bello G, Maurelli M, Schena D, Gisondi P, Girolomoni G. Variations of symptoms of atopic dermatitis and psoriasis in relation to menstrual cycle. *J Am Acad Dermatol* 00:000–000, 2022.
126. Bellinato F, Rosina P, Zarattini M, Gisondi P, Girolomoni G. Dermoscopic features of nevoid melanoma: a retrospective study with systematic literature review. *Ital J Dermatol Venereol* 00:000–000, 2022.
127. Girolomoni G, Maurelli M, Gisondi P. The emerging role of the neuroimmune cytokine interleukin-31 in chronic inflammatory skin diseases. *It J Dermatol Venereol* 00:000–000, 2022.
128. Dal Bello G, Schena D, Girolomoni G. Upadacitinib in patients with resistant atopic dermatitis: a retrospective case-series. *J Eur Acad Dermatol Venereol* 37:e000–e000, 2022.
129. Maurelli M, Colato C, Gisondi P, Girolomoni G. Uncommon non-infectious annular dermatoses. *Indian J Dermatol* 00:000–000, 2022.
130. Bonamonte D, Hansel K, Romita P, Belloni Fortina A, Girolomoni G, Fabbrocini G, Patruno C, Napolitano M, Patrizi A, Argenziano G, Micali G, Pinton PC, Foti C, Stingeni L. Contact allergy in children with and without atopic dermatitis: an Italian multicenter study. *Contact Dermatitis* 00:000–000, 2022.
131. Gisondi P, Maurelli M, Bellinato F, Girolomoni G. Is risankizumab as needed administration a good option for patients with plaque psoriasis? *J Eur Acad Dermatol Venereol* 37:e000–e000, 2022.
132. Gisondi P, Bellinato F, Geat D, Maurelli M, Girolomoni G. Cost per responder of adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis. *Expert Opin Biol Ther* 00:000–000, 2022.
133. Wollenberg A, Arents B, Aszodi N, Avila G, Valle, Barbarot S, Bieber T, Brough HA, Calzavara Pinton P, Christen-Zäch S, Deleuran M, Dittmann M, Dressler C, Fink-Wagner AH, Fosse N, Gáspár K, Gerbens L, Gieler U, Girolomoni G, Gregoriou S, Kinberger M, Mortz CG, Nast A, Nygaard U, Redding M, Rehbinder EM, Ring J, Rossi M, Serra-Baldrich E, Simon D, Szalai ZZ, Szepletowski J, Torrelo A, Werfel T, Flohr C. European guideline (EuroGuiDerm) on atopic eczema – part I: topical therapy. *J Eur Acad Dermatol Venereol* 37:000–000, 2022.
134. Wollenberg A, Arents B, Aszodi N, Avila G, Valle, Barbarot S, Bieber T, Brough HA, Calzavara Pinton P, Christen-Zäch S, Deleuran M, Dittmann M, Dressler C, Fink-Wagner AH, Fosse N, Gáspár K, Gerbens L, Gieler U, Girolomoni G, Gregoriou S, Kinberger M, Mortz CG, Nast A, Nygaard U, Redding M, Rehbinder EM, Ring J, Rossi M, Serra-Baldrich E, Simon D, Szalai ZZ, Szepletowski J, Torrelo A, Werfel T, Flohr C. European Guideline (EuroGuiDerm) on Atopic Eczema – part II: Non-systemic treatments and treatment recommendations for special patient populations. *J Eur Acad Dermatol Venereol* 37:000–000, 2022.
135. Furci A, Bruni M, Geat D, Colato C, Girolomoni G, Schena D. Pyoderma gangrenosum associated with pseudo-Pelger-Huët anomaly in a patient with idiopathic myelofibrosis. *Dermatol Online J* 00:000, 2022.
136. Moar A, Maurelli M, Colato C, Girolomoni G. A man with widespread bullous eruption. *Epidermolysis bullosa acquisita. JEADV Clin Pract* 00:000.000, 2022.
137. Gooderham MJ, Girolomoni G, Moore JO, Silverberg JI, Bissonnette R, Forman S, Peeva E, Biswas P, Valdez H, Chan G. Durability of response to abrocitinib in patients with moderate-to-severe atopic dermatitis after treatment discontinuation in a phase 2b trial. *Dermatol Ther (Heidelb)* 00:000–000, 2022.
138. Bellinato F, Mastrosimini MG, Querzoli G, Gisondi P, Girolomoni G. Dupilumab for recalcitrant Kimura disease. *Dermatol Ther* 00:000–000, 2022.
139. Simpson E, Merola JF, Silverberg JI, Reich K, Warren R, Staumont-Sallé D, Girolomoni G, Papp K, de Bruin-Weller M, Zachariae R, Kurre Olsen C, Wollenberg A. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase 2 and phase 3 trials. *Br J Dermatol* 000:000–000, 2022.
140. Gori N, Chiricozzi A, Calzavara Pinton P, Marsili F, Marzano AV, Amerio P, Battarra V, Campitiello S, Castelli A, Congedo M, Corazza M, Cristaudo A, Fabbrocini G, Fierro MT, Girolomoni G, Malara G, Micali G, Palazzo G, Parodi A, Patrizi A, Pellacani G, Pigatto P, Provenzano E, Romanelli M, Savoia P, Peris K. National information campaign revealed disease characteristic and burden in patients suffering from atopic dermatitis. *J Clin Med* 11:0000, 2022.

141. Gisondi P, Bellinato F, Maurelli M, Geat D, Zabotti A, McGonagle D, Girolomoni G. Reducing the risk of developing psoriatic arthritis in patients with psoriasis. *Psoriasis: Targets and Therapy* 00:000–000, 2022.
142. Gisondi P, Geat D, Bellinato F, Girolomoni G. Use of biologics during the COVID pandemic: Lessons learned from psoriasis. *Expert Opin Biol Ther* 22:000–000, 2022.

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali" e del regolamento (UE) 2016/679 (GDPR). Si attesta inoltre la consapevolezza del rispetto alla responsabilità connesse a dichiarazioni mendaci (PDPR 445/2000 art 76).

Verona 04.08.2022



Prof. Giampiero Girolomoni